SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Obtaining Approval Notice for Supplementary Drug Application and Other Relevant Information
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Esomeprazole Magnesium Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
SHANDONG XINHUA: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on the Progress of Clinical Trial of OAB-14 Dry Suspension
SHANDONG XINHUA: Interim Dividend For the Six Months Ended 30 June 2024
SHANDONG XINHUA: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2024
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
SHANDONG XINHUA: Articles of Association
SHANDONG XINHUA: Final dividend for the year ended 31 December 2023
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Pregabalin Capsules Having Obtained the Drug Registration Certificate
SHANDONG XINHUA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Citicoline Sodium Injection(4ml:0.5g) Having Passed the Generics Consistency Evaluation
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Naloxone Hydrochloride Injection Having Passed the Generics Consistency Evaluation
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Sodium Bicarbonate Injection Having Passed the Generics Consistency Evaluation
SHANDONG XINHUA: Reply Slip for Class Meeting of H Shareholders
SHANDONG XINHUA: Reply Slip for 2023 Annual General Meeting
No Data
No Data